Literature DB >> 22411871

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Margaret Nieborowska-Skorska1, Piotr K Kopinski, Regina Ray, Grazyna Hoser, Danielle Ngaba, Sylwia Flis, Kimberly Cramer, Mamatha M Reddy, Mateusz Koptyra, Tyrone Penserga, Eliza Glodkowska-Mrowka, Elisabeth Bolton, Tessa L Holyoake, Connie J Eaves, Sabine Cerny-Reiterer, Peter Valent, Andreas Hochhaus, Timothy P Hughes, Heiko van der Kuip, Martin Sattler, Wieslaw Wiktor-Jedrzejczak, Christine Richardson, Adrienne Dorrance, Tomasz Stoklosa, David A Williams, Tomasz Skorski.   

Abstract

Chronic myeloid leukemia in chronic phase (CML-CP) is induced by BCR-ABL1 oncogenic tyrosine kinase. Tyrosine kinase inhibitors eliminate the bulk of CML-CP cells, but fail to eradicate leukemia stem cells (LSCs) and leukemia progenitor cells (LPCs) displaying innate and acquired resistance, respectively. These cells may accumulate genomic instability, leading to disease relapse and/or malignant progression to a fatal blast phase. In the present study, we show that Rac2 GTPase alters mitochondrial membrane potential and electron flow through the mitochondrial respiratory chain complex III (MRC-cIII), thereby generating high levels of reactive oxygen species (ROS) in CML-CP LSCs and primitive LPCs. MRC-cIII-generated ROS promote oxidative DNA damage to trigger genomic instability, resulting in an accumulation of chromosomal aberrations and tyrosine kinase inhibitor-resistant BCR-ABL1 mutants. JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. In the present study, inhibition of Rac2 by genetic deletion or a small-molecule inhibitor and down-regulation of mitochondrial ROS by disruption of MRC-cIII, expression of mitochondria-targeted catalase, or addition of ROS-scavenging mitochondria-targeted peptide aptamer reduced genomic instability. We postulate that the Rac2-MRC-cIII pathway triggers ROS-mediated genomic instability in LSCs and primitive LPCs, which could be targeted to prevent the relapse and malignant progression of CML.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22411871      PMCID: PMC3359741          DOI: 10.1182/blood-2011-10-385658

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.

Authors:  Su Chu; Tinisha McDonald; Allen Lin; Sujata Chakraborty; Qin Huang; David S Snyder; Ravi Bhatia
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

2.  Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation.

Authors:  M P King; G Attardi
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

Review 3.  Free radicals, metals and antioxidants in oxidative stress-induced cancer.

Authors:  M Valko; C J Rhodes; J Moncol; M Izakovic; M Mazur
Journal:  Chem Biol Interact       Date:  2006-01-23       Impact factor: 5.192

4.  Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.

Authors:  Kay Barnes; Elizabeth McIntosh; Anthony D Whetton; George Q Daley; Johanne Bentley; Stephen A Baldwin
Journal:  Oncogene       Date:  2005-05-05       Impact factor: 9.867

5.  Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.

Authors:  G P Amarante-Mendes; C Naekyung Kim; L Liu; Y Huang; C L Perkins; D R Green; K Bhalla
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

6.  Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha.

Authors:  S W Kang; H Z Chae; M S Seo; K Kim; I C Baines; S G Rhee
Journal:  J Biol Chem       Date:  1998-03-13       Impact factor: 5.157

7.  Extension of murine life span by overexpression of catalase targeted to mitochondria.

Authors:  Samuel E Schriner; Nancy J Linford; George M Martin; Piper Treuting; Charles E Ogburn; Mary Emond; Pinar E Coskun; Warren Ladiges; Norman Wolf; Holly Van Remmen; Douglas C Wallace; Peter S Rabinovitch
Journal:  Science       Date:  2005-05-05       Impact factor: 47.728

8.  Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.

Authors:  Jeong H Kim; Stephanie C Chu; Jessica L Gramlich; Yuri B Pride; Emily Babendreier; Dharminder Chauhan; Ravi Salgia; Klaus Podar; James D Griffin; Martin Sattler
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

9.  BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

Authors:  Michal O Nowicki; Rafal Falinski; Mateusz Koptyra; Artur Slupianek; Tomasz Stoklosa; Ewa Gloc; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

10.  BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.

Authors:  T Skorski; P Wlodarski; L Daheron; P Salomoni; M Nieborowska-Skorska; M Majewski; M Wasik; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

View more
  69 in total

1.  Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.

Authors:  Yanzhi Du; Yuan Xia; Xiaoling Pan; Zi Chen; Aihua Wang; Kankan Wang; Junmin Li; Ji Zhang
Journal:  Antioxid Redox Signal       Date:  2013-10-24       Impact factor: 8.401

Review 2.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

3.  MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

Authors:  Silvia Maifrede; Esteban Martinez; Margaret Nieborowska-Skorska; Daniela Di Marcantonio; Michael Hulse; Bac Viet Le; Huaqing Zhao; Katarzyna Piwocka; Italo Tempera; Stephen M Sykes; Tomasz Skorski
Journal:  Blood Adv       Date:  2017-08-09

Review 4.  Therapeutic potential of cancer stem cells.

Authors:  Chunguang Yang; Kunlin Jin; Yangping Tong; William Chi Cho
Journal:  Med Oncol       Date:  2015-04-25       Impact factor: 3.064

5.  Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

Authors:  Elisabeth Bolton-Gillespie; Mirle Schemionek; Hans-Ulrich Klein; Sylwia Flis; Grazyna Hoser; Thoralf Lange; Margaret Nieborowska-Skorska; Jacqueline Maier; Linda Kerstiens; Mateusz Koptyra; Martin C Müller; Hardik Modi; Tomasz Stoklosa; Ilona Seferynska; Ravi Bhatia; Tessa L Holyoake; Steffen Koschmieder; Tomasz Skorski
Journal:  Blood       Date:  2013-03-29       Impact factor: 22.113

6.  On the dynamics of neutral mutations in a mathematical model for a homogeneous stem cell population.

Authors:  Arne Traulsen; Tom Lenaerts; Jorge M Pacheco; David Dingli
Journal:  J R Soc Interface       Date:  2012-12-05       Impact factor: 4.118

7.  FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis.

Authors:  Xin Zhang; Genís Campreciós; Pauline Rimmelé; Raymond Liang; Safak Yalcin; Sathish Kumar Mungamuri; Jeffrey Barminko; Valentina D'Escamard; Margaret H Baron; Carlo Brugnara; Dmitri Papatsenko; Stefano Rivella; Saghi Ghaffari
Journal:  Am J Hematol       Date:  2014-07-22       Impact factor: 10.047

8.  BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Authors:  A Slupianek; R Falinski; P Znojek; T Stoklosa; S Flis; V Doneddu; D Pytel; E Synowiec; J Blasiak; A Bellacosa; T Skorski
Journal:  Leukemia       Date:  2012-10-09       Impact factor: 11.528

Review 9.  Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.

Authors:  Antonieta Chavez-Gonzalez; Babak Bakhshinejad; Katayoon Pakravan; Monica L Guzman; Sadegh Babashah
Journal:  Cell Oncol (Dordr)       Date:  2016-09-27       Impact factor: 6.730

10.  Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.

Authors:  M Nieborowska-Skorska; G Hoser; A Hochhaus; T Stoklosa; T Skorski
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.